MicroRNAs in Skin Fibrosis

Andrew Mamalis, Jared Jagdeo

Research output: Chapter in Book/Report/Conference proceedingChapter


The pathogenesis and maintenance of skin fibrosis is a result of complex interactions between a number of cellular pathways, cell types, and extracellular matrix molecules. miRNAs regulate these pathways and contribute to skin fibrosis through TGF-β signaling, ECM deposition, fibroblast proliferation and differentiation, and epithelial-mesenchymal transition (EMT). Some miRNAs up-regulate these processes and are known as profibrotic; others, known as antifibrotic, inhibit them, leading to skin fibrosis. miRNA therapies are aimed at either increasing the levels of antifibrotic miRNAs or decreasing those of profibrotic miRNAs. There are few effective treatments for fibrotic skin diseases, and we believe that future miRNA therapies might alter the management paradigm of skin fibrosis and improve patient outcomes and quality of life.

Original languageEnglish (US)
Title of host publicationMicroRNA in Regenerative Medicine
PublisherElsevier Inc.
Number of pages18
ISBN (Print)9780124058583, 9780124055445
StatePublished - Dec 23 2014


  • Collagen
  • Epithelial-mesenchymal transition
  • Extracellular matrix
  • Fibroblast
  • MicroRNA
  • MiRNA
  • Platelet-derived growth factor
  • Scleroderma
  • Skin fibrosis
  • Therapeutics
  • Transforming growth factor

ASJC Scopus subject areas

  • Immunology and Microbiology(all)


Dive into the research topics of 'MicroRNAs in Skin Fibrosis'. Together they form a unique fingerprint.

Cite this